If the results from the clinical development plans are positive, it may well reflect a paradigm shift for clinical care.

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

Skyrizi is used to treat certain inflammatory conditions, such as plaque psoriasis. The drug starts working after your first dose. Skyrizi is approved by the Food and Drug Administration (FDA ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.